Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
Part of paid clinical trials in Glendale, California.
- Sponsor
- Glendale Adventist Medical Center d/b/a Adventist Health Glendale
- Study ID
- NCT05218044
- Status
- Recruiting
Conditions
- Ductal Carcinoma in Situ
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Cryoablation — PROCEDUREThe cryoprobe tip will be inserted into the breast and directed under ultrasound guidance to the location where the ultrasound visible marker is located. Next, the cryoprobe will be used to freeze a 4 X 3 X 3 cm diameter area of DCIS using two separate 10-minute freeze cycles separated by a single 10-minute thaw cycle. The cryoprobe will remain in place the entire time. After the second freeze, the cryoprobe will be withdrawn from the breast and a bandage will be applied to the skin.
Study Details
Cryoablation or tumor freezing is a percutaneous, office-based procedure that is emerging as a minimally invasive, cost-effective alternative to surgery that is currently being evaluated in clinical trials for the management of for early-stage invasive breast cancer. The investigator will also evaluate the potential of cryoablation as a minimally invasive alternative to surgery for small areas of DCIS by examining its ability to achieve complete ablation of DCIS within the targeted cryoablation zone of necrosis.
Key Dates
- Start date
- Nov 1, 2021
- Status verified
- Mar 2023
- Primary completion
- Nov 1, 2026
- Completion
- Nov 1, 2026
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Other: CryoablationPhase I, single-arm study to evaluate the ability of cryoablation to achieve complete ablation of DCIS in the cryoablation zone of necrosis as a potential alternative to surgery.
Primary Outcome Measure
Ability of cryoablation to achieve complete ablation of DCIS [ Time Frame: 6 months ]
Central Contacts
- Dennis R Holmes, M.D.800-203-5515
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Office of Dennis R. Holmes, M.D., F.A.C.S. | Glendale | California | 91206 | Dennis Holmes, M.D. 800-203-5515 Dennis Holmes, M.D. (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Glendale, CA
By research site
Related Studies
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentPHASE2 · Recruiting · QuantumLeap Healthcare Collaborative · Berkeley, California
- Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)Recruiting · RPCR, Inc. · Stuart, Florida
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituPHASE1 · Recruiting · Finn, Olivera, PhD · Pittsburgh, Pennsylvania
- Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)PHASE2 · Recruiting · University of Florida · Gainesville, Florida